J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hermann, R.
Right arrow Articles by Bethke, T. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hermann, R.
Right arrow Articles by Bethke, T. D.

DRUG INTERACTIONS

The Oral, Once-Daily Phosphodiesterase 4 Inhibitor Roflumilast Lacks Relevant Pharmacokinetic Interactions With Inhaled Budesonide

Robert Hermann, MD, Werner Siegmund, MD, Thomas Giessmann, MD, Kristin Westphal, MD, Anita Weinbrenner, MD, Bernhard Hauns, MD, Felix Reutter, PhD, Gezim Lahu, Karl Zech, PhD and Thomas D. Bethke, MD

From ALTANA Pharma AG, Konstanz, Germany (Dr Hermann, Dr Hauns, Mr Lahu, Dr Zech, and Dr Bethke); the Department of Clinical Pharmacology, University of Greifswald, Greifswald, Germany (Dr Siegmund, Dr Giessmann, Dr Westphal, and Dr Weinbrenner); and ALTANA Pharma Pvt Ltd, Mumbai, India (Dr Reutter).

This open-label, randomized, 3-period crossover study evaluated the pharmacokinetic interaction potential of roflumilast and budesonide following repeated coadministration to healthy male subjects (N = 12). Treatments consisted of oral roflumilast 500 µg, once daily, orally inhaled budesonide 800 µg, twice daily, and concomitant administration of both treatments for 7 days each. Roflumilast and roflumilast N-oxide in plasma and budesonide serum levels were measured by specific assays. Geometric mean test/reference ratios of steady-state pharmacokinetic parameters were evaluated by analysis of variance. Safety and tolerability were monitored. Pharmacokinetic parameters of roflumilast, roflumilast N-oxide, and budesonide after coadministration of roflumilast and budesonide were similar to those after mono-treatment. Compared with budesonide and roflumilast mono-treatments, slightly lower maximum serum/plasma concentration (Cmax) and area under the curve (AUC) values of roflumilast N-oxide and budesonide (ranging from -8% to -16%) were observed with combined treatment. All test/reference ratios were within predefined equivalence acceptance ranges for roflumilast AUC (0.80, 1.25) and Cmax (0.70, 1.43) and for roflumilast N-oxide and budesonide AUC and Cmax (all 0.67, 1.50). Coadministration of roflumilast and budesonide did not alter the steady-state disposition of each other and did not affect safety and tolerability of either drug.

Key Words: Budesonide • Pulmicort® Turbuhaler® • roflumilast • pharmacokinetics • PDE4 inhibitor

Address for correspondence: Thomas D. Bethke, MD, Nycomed Deutschland GmbH, Moltkestr. 4, 78467 Konstanz, Germany.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American College of Clinical Pharmacology